What Is a Secretagogue? A Research Science Explainer

Laboratory test tubes and equipment — what is a secretagogue in research science

What is a secretagogue? The question comes up constantly in peptide research circles, and the answer is simpler than the word sounds. A secretagogue is any substance that causes another substance to be secreted — that is, released by a cell or gland. The term itself is descriptive, not prescriptive: it says nothing about how the substance works, whether it is a peptide or a small molecule, or what research has found about it. It simply labels the functional outcome. This what is a secretagogue guide explains the term exactly as published research uses it, with a special focus on growth hormone secretagogues, the class that dominates the peptide literature.

Research-use-only disclaimer: This article is an educational science explainer for laboratory researchers. It contains no dosage information, no administration instructions, no medical advice, and no efficacy claims for humans. All products referenced are sold strictly for laboratory research use. Nothing here recommends using any compound.

What Is a Secretagogue? The Core Definition

At its most literal, what is a secretagogue has a one-sentence answer: a secretagogue is an agent that promotes the secretion of a substance from a cell. The word combines “secret-” (from secretion) with “-agogue” (from the Greek agōgos, meaning “leading” or “promoting” — the same root found in “pedagogue”). A growth hormone secretagogue, then, is a substance that promotes the secretion of growth hormone. An insulin secretagogue promotes insulin release. The term describes an observed effect in research settings, and researchers use it as a functional category rather than a structural one.

The one-sentence definition

A secretagogue is a substance studied for its ability to stimulate cells or glands to release (secrete) another substance — for example, growth hormone from the pituitary gland. It is a functional label, not a chemical family: peptides, peptide analogues, and small molecules can all be described as secretagogues in published research.

That functional nature is the single most important point for anyone asking what is a secretagogue. Two compounds can both be secretagogues while sharing almost nothing structurally. A synthetic hexapeptide and a non-peptide small molecule may both stimulate growth hormone release through entirely different receptors — yet both are called growth hormone secretagogues in the literature. Understanding the term this way — as a description of what a compound does in an experimental system, not what it is — clears up most of the confusion around it. Researchers can read more about how compounds are compared as research subjects in our selank vs semax research comparison.

What Is a Secretagogue in Published Peptide Research

In the peptide literature, what is a secretagogue almost always resolves to one specific class: growth hormone secretagogues (GHSs). These are the compounds the term most commonly points to in published research, and they are the reason the word appears so often in research-peptide discussions. A growth hormone secretagogue is studied for its ability to stimulate the release of endogenous growth hormone from the anterior pituitary gland — “endogenous” meaning the body’s own hormone, rather than an administered one.

But growth hormone secretagogues are not the only secretagogues in the scientific vocabulary. The table below maps the main classes researchers encounter, so the term’s scope stays honest.

Secretagogue classSubstance whose release is studiedWell-known examples in published research
Growth hormone secretagogues (GHSs)Growth hormone (GH) from the anterior pituitaryGHRP-6, GHRP-2, ipamorelin, hexarelin, MK-677 (ibutamoren)
GHRH analoguesGrowth hormone, via the GHRH receptorSermorelin, tesamorelin, CJC-1295
Insulin secretagoguesInsulin from pancreatic beta cellsSulfonylureas, meglitinides
Secretin/CCK secretagoguesDigestive secretionsCholecystokinin-releasing peptides
Prolactin secretagoguesProlactin from the anterior pituitaryTRH (in experimental settings)

Notice the pattern: every row answers what is a secretagogue the same way — a substance studied for prompting release of something else. In peptide research, though, the conversation is overwhelmingly about the first two rows: growth hormone secretagogues and GHRH analogues. The rest of this guide focuses there, because that is where the term does its real work in the research literature. For context on how individual research peptides are positioned, see our research overview of Semax nasal spray and Selank nasal spray formats studied in research settings.

Scientist examining samples with a microscope — secretagogue research in the lab
Photo: Pexels

The Discovery Timeline: How Growth Hormone Secretagogues Entered Research

The story of what is a secretagogue in the growth hormone context is really a story of accidental discovery followed by decades of receptor hunting. The milestones below trace how the class emerged in published research.

1970s — Enkephalin analogues with an unexpected effect

Researchers working with synthetic enkephalin analogues noticed that certain short peptides could stimulate growth hormone release in experimental systems. The effect was unexpected — these compounds were not designed as GH stimulators — but it opened a new research direction.

1984 — GHRP-6 enters the literature

C.Y. Bowers and colleagues described growth hormone-releasing peptide 6 (GHRP-6), a synthetic hexapeptide that potently stimulated GH release. GHRP-6 became the prototype of the growth hormone-releasing peptide family and one of the most cited reference compounds in secretagogue research.

1996 — The receptor is cloned

Howard and colleagues cloned the growth hormone secretagogue receptor (GHS-R, now GHSR-1a) from pituitary and hypothalamic tissue. Finding the receptor proved these compounds were acting through a dedicated signaling pathway — and implied an undiscovered natural ligand was out there.

1998 — Ipamorelin described

Researchers at Novo Nordisk (Raun and colleagues) described ipamorelin, a pentapeptide growth hormone secretagogue noted in published research for its selectivity at the ghrelin receptor. It added a structurally distinct member to the GHS family.

1999 — Ghrelin, the natural ligand, is found

Kojima, Kangawa, and colleagues isolated ghrelin from rat stomach and identified it as the endogenous ligand for the growth hormone secretagogue receptor — the missing natural partner the 1996 cloning work had predicted. This completed the biological picture of what is a secretagogue in the GH context: synthetic compounds were mimicking a real stomach-derived hormone.

2000s — Non-peptide secretagogues emerge

Small-molecule growth hormone secretagogues such as MK-677 (ibutamoren) were developed and studied, showing that secretagogue activity was not limited to peptides at all — reinforcing the point that the term is functional, not structural.

That timeline is why the modern answer to what is a secretagogue is so settled in the GH space: a class of compounds, peptide and non-peptide, studied for stimulating endogenous growth hormone release through the ghrelin (GHSR-1a) receptor or the GHRH receptor. The Wikipedia overview of secretagogues gives the general definition, while PubMed indexes the primary discovery papers.

Test tubes with colored liquids — growth hormone secretagogue research compounds
Photo: Pexels

How Researchers Classify Secretagogues: Two Receptor Pathways

Once you know what is a secretagogue, the next research question is how a given one works — and in the GH space, that comes down to two receptor pathways. Growth hormone secretagogues studied in published research act through either the ghrelin receptor (GHSR-1a) or the growth hormone-releasing hormone (GHRH) receptor. The distinction matters because the two pathways represent different signaling routes to the same studied outcome: pituitary GH release.

Ghrelin-pathway secretagogues — GHRP-6, GHRP-2, ipamorelin, hexarelin, and the small molecule MK-677 — are studied as agonists or mimetics of ghrelin at GHSR-1a, a receptor expressed in the hypothalamus and pituitary. Ghrelin itself, the endogenous ligand discovered in 1999, is a 28-amino-acid peptide produced mainly in the stomach. The Wikipedia entry on ghrelin summarizes its discovery and receptor pharmacology.

GHRH-pathway compounds — sermorelin, tesamorelin, CJC-1295 — are analogues of growth hormone-releasing hormone itself and act through the GHRH receptor on pituitary somatotrophs. They are secretagogues in the same functional sense (they promote GH release), but through the body’s primary stimulatory GH pathway rather than the ghrelin pathway. Some are approved medicines in specific indications — tesamorelin, for instance, is FDA-approved for HIV-associated lipodystrophy — which is a regulatory fact about those specific products, not a statement about the class. The FDA’s drug information pages explain what approval status means for any given product.

This two-pathway picture is the working framework researchers use when they ask what is a secretagogue about a specific compound: identify the receptor, and the classification follows. Our Semax 10mg and Selank 10mg research listings carry the same compound-level framing — structure, origin, and research status stated plainly.

What a Secretagogue Is Not

Clearing up the negative space helps as much as the definition when answering what is a secretagogue. A secretagogue is not the hormone itself: a growth hormone secretagogue is not growth hormone, just as a match is not a fire. It is studied for triggering release of the body’s own stores rather than supplying the substance directly. That distinction shapes how the compounds are discussed in research: studies of secretagogues typically measure endogenous hormone pulses, not the administered compound’s direct activity.

A secretagogue is also not a single chemical family, as the timeline above shows — peptides, peptide analogues, and small molecules all qualify. And in research-peptide commerce, “secretagogue” is not a regulatory category: it confers no approval status and implies none. Every compound discussed here is handled as a research compound for laboratory investigation, full stop.

Two scientists working with microscopes and test tubes — studying what is a secretagogue
Photo: Pexels

Key takeaways: what is a secretagogue

1. A secretagogue is any substance studied for promoting the secretion of another substance — a functional label, not a chemical family. 2. In peptide research, the term almost always means growth hormone secretagogues: compounds studied for stimulating endogenous GH release. 3. Two receptor pathways organize the class: the ghrelin receptor (GHRP-6, ipamorelin, ghrelin, MK-677) and the GHRH receptor (sermorelin, tesamorelin, CJC-1295). 4. The class grew from 1970s enkephalin-analogue observations through the 1999 discovery of ghrelin, the natural ligand. 5. “Secretagogue” implies no approval status — every compound here is a research compound for laboratory use only. (Research framing only — not a usage recommendation.)

What Is a Secretagogue? Frequently Asked Questions

Quick answers to the questions researchers ask most about what is a secretagogue — all in research framing.

What is a secretagogue in simple terms?

A secretagogue is a substance that causes cells or glands to release (secrete) another substance. A growth hormone secretagogue is studied for stimulating the pituitary gland to release the body’s own growth hormone. The term describes the functional effect observed in research, not the compound’s chemical structure.

What is a secretagogue’s relationship to ghrelin?

Ghrelin is the endogenous (naturally occurring) ligand of the growth hormone secretagogue receptor, discovered in 1999 by Kojima, Kangawa, and colleagues. Synthetic growth hormone secretagogues such as GHRP-6 and ipamorelin are studied as compounds acting through that same receptor — which is why the receptor is called the growth hormone secretagogue receptor (GHSR-1a).

Are all secretagogues peptides?

No. While many studied growth hormone secretagogues are peptides or peptide analogues (GHRP-6, ipamorelin, sermorelin), the class also includes small non-peptide molecules such as MK-677 (ibutamoren). “Secretagogue” is a functional label — it says what a compound is studied for doing, not what it is made of.

What is the difference between a secretagogue and a GHRH analogue?

Both are studied for promoting growth hormone release, but through different receptors. GHRH analogues (sermorelin, tesamorelin, CJC-1295) act through the growth hormone-releasing hormone receptor, while ghrelin-pathway secretagogues (GHRP-6, ipamorelin, MK-677) act through the ghrelin receptor (GHSR-1a). In functional terms both are secretagogues; mechanistically they are distinct research classes.

Are secretagogues FDA-approved?

“Secretagogue” is not a regulatory category and confers no approval status. A few specific compounds in this space hold approvals for specific indications (for example, tesamorelin for HIV-associated lipodystrophy), but most research secretagogues discussed in the peptide literature are not FDA-approved drugs and are handled as research compounds for laboratory investigation only.

Where can researchers source secretagogue compounds for research use?

For laboratory research use, peptide compounds are supplied as research vials by research-use suppliers — for example, our Semax 10mg and Selank 10mg research listings. Sourcing should be limited to suppliers explicit about research-use-only status. Nothing here is a recommendation for human use.

What Is a Secretagogue? Final Research Notes

The honest answer to what is a secretagogue is refreshingly plain: a substance studied for making something else come out. In peptide research, that “something else” is almost always growth hormone, and the substances are the GHS and GHRH-analogue families traced through the discovery timeline above — from 1970s enkephalin analogues to GHRP-6, through the cloning of the ghrelin receptor and the 1999 discovery of ghrelin itself, to modern small molecules. The term is functional, the pathways are two, and the regulatory reality is research-use-only.

Kept in that frame — definition, classes, timeline, receptors — the question what is a secretagogue has a stable, useful answer that needs no human-use claims to be worth knowing. For researchers mapping the wider peptide landscape, our selank vs semax comparison shows how individual research compounds are profiled in the same descriptive style.

Leave a Comment

Cart0
Cart0

Research Verification Required

This website contains research compounds available exclusively for qualified researchers and laboratory professionals. By entering, you confirm: